Press release

Press release

February 7, 2018

Follicum Phase IIa study of FOL-005 against hair loss approved by the German Medicines Agency

Lund, Sweden, February 7, 2018: Follicum AB (“Follicum” or “the company”) today announced it has received approval from the German Medicines Agency (BfArM) and German Ethics Committee to commence a Phase IIa clinical trial in Germany with its lead candidate FOL-005 on patients with Alopecia (hair loss). The trial will include approximately 60 patients and […]

February 1, 2018

Lund University Bioscience AB has decided to distribute its shares in Follicum AB

Follicum AB (”Follicum”) announce that Lund University Bioscience AB (LU Bio) has had an extraordinary general meeting 31 January, 2018. It was decided that the company’s shares in Follicum, will be distributed to its LU Bio’s shareholders. The distribution is planned to occur during week 6, 2018. LU Bio has 2 320 370 shares in […]

January 29, 2018

Follicum identifies receptors in insulin-producing cells for potential new class of diabetes drugs

Lund, Sweden, January 29, 2018. Follicum AB (“Follicum”) today announced that it has successfully mapped the receptors in insulin-producing cells that bind the company’s peptides. The new knowledge represents an important milestone in the continued development of the company’s diabetes project and opens the possibility of the identified receptors becoming potential drug targets for stimulating […]

January 25, 2018

Follicum AB: Disclosure notice

As a result of the preferential rights issue in Follicum AB (“Follicum”) in October 2017, the holding of the shareholder, Lund University Bioscience AB’s has decreased to less than ten percent of votes and equity. Lund University Bioscience AB is one of the main shareholders in Follicum. As a result of the recently completed preferential […]

November 23, 2017

Follicum receives patent approval in China

Follicum AB (“Follicum”) today announces that the Chinese Patent Office (SIPO) has granted the company’s patent application for stimulation of hair growth. Thanks to SIPO’s grant of patent number ZL 201280049850.X, Follicum has protection in China until 2032. The patent protects the company’s peptides in general and for the stimulation of hair growth specifically. CEO […]

November 20, 2017

Follicum applies for the start of a Phase II study at the German Medicines Agency

Follicum AB (“Follicum” or “the company”) today announced that the company has filed an application for the initiation of a Phase IIa clinical trial with FOL-005 on scalp to study hair growth to the German Medicines Agency, BfArM and to the Ethics Committees. The goal is to start the study after approval by the authorities […]

November 9, 2017

Follicum expands its collaboration with two prominent hair clinics for the implementation of the next Phase IIa study with FOL-005

Follicum AB (“Follicum”) recently made a preferential share issue which provided the company with SEK 23.5 million before costs. The liquidity paid to the company is partly intended to finance a Phase IIa clinical trial with the company’s drug candidate FOL-005. Follicum hereby announces that the company has chosen to work with the Clinical Research […]

September 11, 2017

Follicum’s diabetes project receives a grant from the Novo Nordisk Foundation

Follicum AB (“Follicum”) today announces that Professor Jan Nilsson´s research group at the Clinical Research Center, Lund University has been granted 400 000 Danish crowns from the Novo Nordisk Foundation to carry out pre-clinical diabetes studies with Follicum’s peptides. The aim of the pre-clinical experiments is to study the effects and mechanisms of action of […]